Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LENZ Therapeutics

已收盘 01-07 16:00:00 EST

16.31

-0.54

-3.20%

盘后16.91

+0.60+3.68%

18:39 EST

最高17.51	最低16.11	成交量122.99万
今开17.01	昨收16.85	日振幅8.31%
总市值5.10亿	流通市值2.56亿	总股本3,129万
成交额2,059万	换手率7.84%	流通股本1,569万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":16.31,"timestamp":1767819600000,"preClose":16.85,"halted":0,"volume":1229927,"hourTrading":{"tag":"盘后","latestPrice":16.91,"preClose":16.31,"latestTime":"18:39 EST","volume":31165,"amount":512019.3926,"timestamp":1767829165961},"delay":0,"floatShares":15692500,"shares":31289969,"eps":-2.10871,"marketStatus":"已收盘","change":-0.54,"latestTime":"01-07 16:00:00 EST","open":17.01,"high":17.51,"low":16.11,"amount":20592499.261001,"amplitude":0.083086,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.10871,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1767862800000},"marketStatusCode":5,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":16.85,"preHourTrading":{"tag":"盘前","latestPrice":16.99,"preClose":16.85,"latestTime":"09:28 EST","volume":520,"amount":8797.696960000001,"timestamp":1767796096044},"postHourTrading":{"tag":"盘后","latestPrice":16.91,"preClose":16.31,"latestTime":"18:39 EST","volume":31165,"amount":512019.3926,"timestamp":1767829165961},"volumeRatio":1.830651,"impliedVol":1.041,"impliedVolPercentile":0.8457},"requestUrl":"/m/hq/s/LENZ","defaultTab":"news","newsList":[{"id":"1172606657","title":"Lenz Therapeutics 公布2025年第四季度初步未经审计财务业绩及近期企业动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1172606657","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172606657?lang=zh_cn&edition=full","pubTime":"2026-01-08 06:09","pubTimestamp":1767823749,"startTime":"0","endTime":"0","summary":"Lenz Therapeutics 已发布其2025年第四季度的初步未经审计财务业绩，并同步更新了公司近期的业务进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","LENZ","BK4539"],"gpt_icon":0},{"id":"2601035809","title":"美股异动 | MRT-8102一期试验数据积极 Monte Rosa Therapeutics(GLUE.US)盘前暴涨超42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601035809","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601035809?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:24","pubTimestamp":1767795857,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，Monte Rosa Therapeutics盘前暴涨超42%，报22.76美元。消息面上，Monte Rosa Therapeutics正在进行的MRT-8102一期试验的中期数据显示，在心血管和心脏代谢疾病中C反应蛋白水平降低。在心血管疾病风险升高的受试者中，正处于研发阶段用于治疗NLRP3/IL-1/IL-6驱动的炎症性疾病的NEK7靶向分子胶降解剂MRT-8102显示出快速且持久的全身炎症减轻效果。经过四周的MRT-8102治疗后，C反应蛋白水平下降了85%，94%的研究参与者达到了低于2 mg/L的CRP值，这一阈值与降低的心血管疾病风险相关联。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","LENZ","MRT","BK4139","GLUE","BK4230","BK4539"],"gpt_icon":0},{"id":"2601936805","title":"Vera Therapeutics的肾病药物获美国FDA优先审查","url":"https://stock-news.laohu8.com/highlight/detail?id=2601936805","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601936805?lang=zh_cn&edition=full","pubTime":"2026-01-07 21:26","pubTimestamp":1767792390,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4585","BK4007","BK4139","BK4539","LENZ","VERA","BK4588"],"gpt_icon":0},{"id":"2601084320","title":"Stoke Therapeutics, Inc.盘中异动 大幅上涨5.02%报34.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601084320","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601084320?lang=zh_cn&edition=full","pubTime":"2026-01-07 00:42","pubTimestamp":1767717730,"startTime":"0","endTime":"0","summary":"北京时间2026年01月07日00时42分，Stoke Therapeutics, Inc.股票出现波动，股价大幅上涨5.02%。Stoke Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.14%。其相关个股中，Alumis Inc.、Lexaria Bioscience Corp C/Wts 14/01/2026 、Seastar Medical Holding Corp C/Wts 28/10/2027 涨幅较大，Pmgc Holdings Inc.、Cyclerion Therapeutics, Inc.、Transcode Therapeutics, Inc.较为活跃，换手率分别为2156.83%、1600.39%、233.97%，振幅较大的相关个股有Seastar Medical Holding Corp C/Wts 28/10/2027 、Lexaria Bioscience Corp C/Wts 14/01/2026 、Alumis Inc.，振幅分别为294.74%、161.40%、71.00%。Stoke Therapeutics, Inc.公司简介：Stoke Therapeutics Inc 是一家致力于利用 RNA 医药开发来恢复蛋白质表达的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107004211a4a42806&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107004211a4a42806&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","STOK","BK4539","BK4007"],"gpt_icon":0},{"id":"2601481542","title":"Lexeo Therapeutics, Inc.盘中异动 快速下跌5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601481542","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601481542?lang=zh_cn&edition=full","pubTime":"2026-01-05 23:18","pubTimestamp":1767626298,"startTime":"0","endTime":"0","summary":"北京时间2026年01月05日23时18分，Lexeo Therapeutics, Inc.股票出现异动，股价快速跳水5.15%。Lexeo Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.76%。Lexeo Therapeutics, Inc.公司简介：Lexeo Therapeutics Inc 是一家临床阶段的基因药物公司，致力于通过应用开创性科学从根本上改变疾病的治疗方式来改变医疗保健。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010523181897a10e9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010523181897a10e9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LXEO","LENZ","BK4539","BK4007"],"gpt_icon":0},{"id":"2601838580","title":"Briacell Therapeutics Corp C/Wts 26/02/2026(To Pur Com)盘中异动 早盘股价大涨9.55%报0.063美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601838580","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601838580?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:39","pubTimestamp":1767623944,"startTime":"0","endTime":"0","summary":"北京时间2026年01月05日22时39分，Briacell Therapeutics Corp C/Wts 26/02/2026股票出现波动，股价大幅上涨9.55%。Briacell Therapeutics Corp C/Wts 26/02/2026股票所在的生物技术行业中，整体跌幅为0.71%。Briacell Therapeutics Corp C/Wts 26/02/2026公司简介：BriaCell Therapeutics Corp是一家临床阶段的生物技术公司，专注于开发用于癌症治疗的免疫疗法。BriaCell参与临床合作，探索联合疗法，以增强癌症治疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105223905953c0431&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105223905953c0431&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","BK4539","LENZ","BCTXW"],"gpt_icon":0},{"id":"2601387836","title":"Gyre Therapeutics, Inc.盘中异动 快速上涨9.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601387836","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601387836?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:32","pubTimestamp":1767623538,"startTime":"0","endTime":"0","summary":"北京时间2026年01月05日22时32分，Gyre Therapeutics, Inc.股票出现异动，股价急速上涨9.77%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.33%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家商业阶段的制药公司，开发和商业化针对器官疾病的小分子抗炎和抗纤维化药物，特别关注器官纤维化。该公司的可报告部门是 Gyre Pharmaceuticals，该公司从在中国销售 艾思瑞和某些仿制药、Gyre 和其他部门获得最大收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105223219a49f643c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105223219a49f643c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","GYRE","BK4139","BK4539"],"gpt_icon":0},{"id":"1103946230","title":"Lenz Therapeutics与Lunatus就Vizz™在中东地区达成独家商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1103946230","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103946230?lang=zh_cn&edition=full","pubTime":"2026-01-05 21:01","pubTimestamp":1767618073,"startTime":"0","endTime":"0","summary":"Lenz Therapeutics与Lunatus宣布，双方已就Vizz™产品在中东市场达成独家商业化合作伙伴关系。此次合作将聚焦于该区域的市场拓展与产品推广。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","LENZ","BK4007"],"gpt_icon":0},{"id":"2600235940","title":"Mineralys Therapeutics：靶向醛固酮，重塑心肾代谢疾病治疗格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2600235940","media":"药研前瞻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600235940?lang=zh_cn&edition=full","pubTime":"2026-01-04 19:29","pubTimestamp":1767526153,"startTime":"0","endTime":"0","summary":"摘要Mineralys Therapeutics 是一家临床阶段的生物制药公司，其全部战略核心与未来价值均寄托于一款名为Lorundrostat的口服、高选择性醛固酮合成酶抑制剂。Mineralys的创新逻辑建立在一个明确的医学认知上：醛固酮失调是多种心肾疾病共同的关键病理驱动因子。同时，高血压及其他CRMS疾病会导致过早发病和死亡，二者相互影响，形成恶性循环。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104205556a6f1f943&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104205556a6f1f943&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4539","LENZ","BK4139","MLYS"],"gpt_icon":0},{"id":"2595773919","title":"Neurosense Therapeutics Ltd.盘中异动 早盘快速下挫5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595773919","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595773919?lang=zh_cn&edition=full","pubTime":"2025-12-30 23:28","pubTimestamp":1767108514,"startTime":"0","endTime":"0","summary":"北京时间2025年12月30日23时28分，Neurosense Therapeutics Ltd.股票出现异动，股价大幅下跌5.26%。截至发稿，该股报0.720美元/股，成交量5.755万股，换手率0.19%，振幅3.55%。Neurosense Therapeutics Ltd.股票所在的生物技术行业中，整体跌幅为0.79%。Neurosense Therapeutics Ltd.公司简介：NeuroSense Therapeutics Ltd是一家临床阶段的生物技术公司，专注于发现和开发患有衰弱性神经退行性疾病的患者的治疗方法，这些疾病包括肌萎缩性侧索硬化症，阿尔茨海默病和帕金森病等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230232835a6e1e64b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230232835a6e1e64b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NRSN","BK4539","LENZ","BK4139"],"gpt_icon":0},{"id":"2595780781","title":"强生公司完成收购Halda Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2595780781","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595780781?lang=zh_cn&edition=full","pubTime":"2025-12-29 21:05","pubTimestamp":1767013505,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE000M9KFDE8.USD","LU1032466523.USD","LU2602419157.SGD","BK4592","IE00BSNM7G36.USD","LU2129689431.USD","LU1894683348.USD","IE0002141913.USD","LU1778281490.HKD","LU0795875086.SGD","LU0234570918.USD","LU1061106388.HKD","LU1066053197.SGD","BK4139","IE00BGHQF631.EUR","LU0889566641.SGD","IE00BLSP4452.SGD","IE0009355771.USD","LU1267930813.SGD","BK4585","IE00B19Z3B42.SGD","LU0985320562.USD","LU2112291526.USD","BK4007","LU0689626769.HKD","LU2129689514.USD","LU1162221912.USD","LU1221951129.SGD","SG9999002232.USD","LU1196500208.SGD","SG9999002224.SGD","LU2430703251.USD","LU0070217475.USD","BK4581","LU1718418525.SGD","BK4532","LU1935042991.SGD","LU1585245621.USD","LU0640476718.USD","BK4568","LU2133065610.SGD","IE00B2B36J28.USD","LU0795875169.SGD","LENZ","LU0234572021.USD","JNJ","LU0289739699.SGD","IE00BVYPNV92.GBP","IE00BKVL7J92.USD","LU1674673428.USD"],"gpt_icon":0},{"id":"2594294036","title":"Quince Therapeutics, Inc.盘中异动 早盘股价大跌5.05%报3.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2594294036","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594294036?lang=zh_cn&edition=full","pubTime":"2025-12-26 22:52","pubTimestamp":1766760723,"startTime":"0","endTime":"0","summary":"北京时间2025年12月26日22时52分，Quince Therapeutics, Inc.股票出现异动，股价急速跳水5.05%。Quince Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.22%。Quince Therapeutics, Inc.公司简介：Quince Therapeutics Inc 是一家临床前阶段的生物制药公司，专注于推进针对衰弱和罕见疾病的精准治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251226225204a6d31f8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251226225204a6d31f8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","QNCX","LENZ","BK4007","BK4539"],"gpt_icon":0},{"id":"2593734104","title":"2026美股生物科技板块怎么投资？杰富瑞：关注这6大首选股、7大潜力标的和5大并购目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2593734104","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593734104?lang=zh_cn&edition=full","pubTime":"2025-12-25 06:00","pubTimestamp":1766613621,"startTime":"0","endTime":"0","summary":"杰富瑞近日发布了关于2026年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。","market":"sh","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385521.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"2026美股生物科技板块怎么投资？杰富瑞：关注这6大首选股、7大潜力标的和5大并购目标","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["SLDB","TNGX","ORIC","TYRA","TSHA","LENZ"],"gpt_icon":1},{"id":"2594289326","title":"Inhibikase Therapeutics, Inc.盘中异动 大幅拉升5.97%报1.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2594289326","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594289326?lang=zh_cn&edition=full","pubTime":"2025-12-25 01:46","pubTimestamp":1766598388,"startTime":"0","endTime":"0","summary":"北京时间2025年12月25日01时46分，Inhibikase Therapeutics, Inc.股票出现波动，股价快速上涨5.97%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.05%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122501462897a0a77d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122501462897a0a77d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","LENZ","BK4539","IKT"],"gpt_icon":0},{"id":"2594282908","title":"Whitehawk Therapeutics, Inc.盘中异动 大幅上涨5.28%报2.79美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2594282908","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594282908?lang=zh_cn&edition=full","pubTime":"2025-12-24 23:20","pubTimestamp":1766589646,"startTime":"0","endTime":"0","summary":"北京时间2025年12月24日23时20分，Whitehawk Therapeutics, Inc.股票出现异动，股价快速上涨5.28%。Whitehawk Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.49%。其相关个股中，奥麦罗制药、Indaptus Therapeutics, Inc.、Dermata Therapeutics Inc C/Wts 涨幅较大，Dermata Therapeutics, Inc.、Indaptus Therapeutics, Inc.、Citius Pharmaceuticals, Inc.较为活跃，换手率分别为1766.77%、1194.23%、59.51%，振幅较大的相关个股有Briacell Therapeutics Corp C/Wts 26/02/2026、Citius Pharmaceuticals, Inc.、Indaptus Therapeutics, Inc.，振幅分别为62.58%、52.88%、32.82%。Whitehawk Therapeutics, Inc.公司简介：Whitehawk Therapeutics Inc 是一种临床前阶段的肿瘤治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224232047953b9d96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224232047953b9d96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","WHWK","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2593047013","title":"美股异动 | 与吉利德科学(GILD.US)达成出售实验性抗癌资产协议 Repare Therapeutics(RPTX.US)盘前一度大涨约20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593047013","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593047013?lang=zh_cn&edition=full","pubTime":"2025-12-24 22:19","pubTimestamp":1766585945,"startTime":"0","endTime":"0","summary":"该公司已与吉利德科学达成资产购买协议，收购其实验性抗癌疗法RP-3467，交易总价值最高可达3000万美元","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20251224/20251224222230_71916.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251224/20251224222230_71916.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"09853388b565e5412a3d944672ba7d17","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1430594728.SGD","BK4578","BK4539","SG9999015945.SGD","LU2089984988.USD","LU0058720904.USD","LU0823416689.USD","SG9999015978.USD","LU1585245621.USD","LU0109394709.USD","LU0289739699.SGD","BK4007","IE0002270589.USD","LU0889565916.HKD","SG9999015986.USD","IE00BKVL7J92.USD","BK4588","IE00B19Z3581.USD","IE00B3T34201.USD","IE00B19Z3B42.SGD","SG9999015952.SGD","LU1066051498.USD","LU2087621335.USD","BK4583","LU2324357040.USD","LU0320765992.SGD","BK4139","LU1778281490.HKD","IE00BZ1G4Q59.USD","LU0234570918.USD","LU1066053197.SGD","BK4532","LU0114720955.EUR","LU1839511570.USD","IE00BSNM7G36.USD","RPTX","BK4585","LU1571399168.USD","LU1674673691.USD","BK4550","IE00B7SZLL34.SGD","BK4566","GILD","LENZ","LU1674673428.USD","BK4568","LU0882574055.USD","LU2468319806.SGD"],"gpt_icon":0},{"id":"2593444029","title":"基因治疗公司Frontera Therapeutics-B  递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2593444029","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593444029?lang=zh_cn&edition=full","pubTime":"2025-12-24 10:20","pubTimestamp":1766542801,"startTime":"0","endTime":"0","summary":"览富财经网讯：12月23日，据港交所网站披露，12月23日，Frontera Therapeutics - B递表港交所拟于港交所主板上市。据招股书披露，Frontera Therapeutics是一家处于临床阶段的基因治疗公司，专注于创 新疗法的研发，具有国际化业务布局，致力于为世界各地的患者提供安全、有效且可负担的基因治疗方案。自2019年成立以来，一直致力于自主开发创新的rAAV基因疗法。Frontera Therapeutics 目前没有任何产品获准商业销售，并于往绩记录期间录得亏损。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202512/24/20251224320488.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202512/24/20251224320488.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251224/31887833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["HEXmain","BK4539","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2593175614","title":"Atossa Therapeutics, Inc.盘中异动 早盘股价大跌5.01%报0.681美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593175614","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593175614?lang=zh_cn&edition=full","pubTime":"2025-12-23 23:58","pubTimestamp":1766505485,"startTime":"0","endTime":"0","summary":"北京时间2025年12月23日23时58分，Atossa Therapeutics, Inc.股票出现波动，股价快速下挫5.01%。截至发稿，该股报0.681美元/股，成交量62.8961万股，换手率0.49%，振幅4.35%。Atossa Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.07%。Atossa Therapeutics, Inc.公司简介：Atossa Therapeutics Inc 是一家临床阶段的生物制药公司，在肿瘤学领域未满足的医疗需求领域开发专有药物。该公司正在开发的用于治疗乳腺癌和其他乳腺疾病的药物是 Endoxifen。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122323580597a09c2b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122323580597a09c2b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ATOWW","BK4539","ATOS","LENZ","BK4007"],"gpt_icon":0},{"id":"2593419675","title":"【新股IPO】Frontera Therapeutics - B向港交所主板递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2593419675","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593419675?lang=zh_cn&edition=full","pubTime":"2025-12-23 23:15","pubTimestamp":1766502959,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所12月23日披露，Frontera Therapeutics - B向港交所主板递交上市申请，瑞银集团、国泰海通为联席保荐人。公司是一家处于临床阶段的基因治疗公司，自2019年成立以来，公司一直致力于自主开发创新的重组腺相关病毒基因疗法。公司已开发出一条差异化且临床进展领先的管线，具全球同类最佳潜力，特别是针对眼科及心血管疾病。","market":"hk","thumbnail":"https://static.szfiu.com/news/20220324/ODFiZjIzMmMyMWE2ZjBhMTAzMDA1NjgwOTQz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/ODFiZjIzMmMyMWE2ZjBhMTAzMDA1NjgwOTQz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1972127","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","BK4139","HEXmain","LENZ"],"gpt_icon":0},{"id":"2593343466","title":"Marker Therapeutics, Inc.盘中异动 早盘股价大涨5.47%报1.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593343466","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593343466?lang=zh_cn&edition=full","pubTime":"2025-12-22 23:56","pubTimestamp":1766419011,"startTime":"0","endTime":"0","summary":"北京时间2025年12月22日23时56分，Marker Therapeutics, Inc.股票出现异动，股价快速拉升5.47%。截至发稿，该股报1.35美元/股，成交量11.3981万股，换手率0.68%，振幅4.69%。Marker Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.77%。Marker Therapeutics, Inc.公司简介：Marker Therapeutics Inc 是一家临床阶段的免疫肿瘤学公司，专门从事用于治疗血液系统恶性肿瘤和实体瘤适应症的新型基于 T 细胞的免疫疗法和基于肽的疫苗的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122223565197a08eaf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122223565197a08eaf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4539","MRKR","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.graphitebio.com","stockEarnings":[{"period":"1week","weight":0.0453},{"period":"1month","weight":-0.3694},{"period":"3month","weight":-0.6533},{"period":"6month","weight":-0.5082},{"period":"1year","weight":-0.3819},{"period":"ytd","weight":0.0531}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":0.0089},{"period":"3month","weight":0.0278},{"period":"6month","weight":0.1054},{"period":"1year","weight":0.162},{"period":"ytd","weight":0.0145}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"LENZ Therapeutics, Inc.于2017年6月1日加拿大安大略省注册成立，并于2019年10月在特拉华州重新注册。他们是一家临床阶段的下一代基因编辑公司，利用高效靶向基因整合开发新型疗法有可能治愈范围广泛的严重和危及生命的疾病。他们正在开创一种精确的基因编辑方法，以实现医学上最难以实现的目标之一：精确“找到并替换”基因组中的任何基因。他们的下一代基因编辑平台使他们能够精确地纠正突变，用正常基因替换整个致病基因，或将新基因插入预定的安全位置。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.12508},{"month":2,"riseRate":0.5,"avgChangeRate":0.077415},{"month":3,"riseRate":0.25,"avgChangeRate":-0.098838},{"month":4,"riseRate":0.5,"avgChangeRate":-0.02248},{"month":5,"riseRate":0.25,"avgChangeRate":-0.134416},{"month":6,"riseRate":0.75,"avgChangeRate":0.05507},{"month":7,"riseRate":0.6,"avgChangeRate":0.05308},{"month":8,"riseRate":0.4,"avgChangeRate":0.016536},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}